As the Business Development Lead at Prazer Therapeutics, Heejin Kim drives strategic partnerships and corporate development initiatives with global partners and investors. She has played a pivotal role in securing multiple transactions, including co-development agreements with Yuhan and Daewon, and successfully led the engagement of Johnson & Johnson as the lead investor in Prazer’s recent Series B fundraising. As a US patent agent and molecular biologists by training, Heejin’s approach focuses on maximizing asset value and mitigating risk by anchoring deal structures in a robust intellectual property strategy and effectively navigating scientific complexities to align partner interests.